Septerna Inc (SEPN)

Currency in USD
42.60
+0.74(+1.77%)
Closed·
42.600.00(0.00%)
·
Earnings results expected in NaN days
SEPN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
40.6042.88
52 wk Range
21.3153.34
Key Statistics
Prev. Close
42.6
Open
41.27
Day's Range
40.6-42.88
52 wk Range
21.31-53.34
Volume
337.79K
Average Volume (3m)
392.81K
1-Year Change
83.1077%
Book Value / Share
9.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SEPN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
59.22
Upside
+39.02%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Septerna Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 59.22
(+39.02% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy60.00+40.85%49.00Maintain10/11/2026
Guggenheim
Buy65.00+52.58%51.00Maintain06/11/2026
Wells Fargo
Buy61.00+43.19%50.00Maintain04/11/2026
JPMorgan
Buy48.00+12.68%38.00Maintain19/08/2026
Truist Securities
Buy59.00+38.50%43.00Maintain13/08/2026

Earnings

Latest Release
09/11/2026
EPS / Forecast
-0.57 / -0.78
Revenue / Forecast
18.88M / --
EPS Revisions
Last 90 days

SEPN Income Statement

Compare SEPN to Peers and Sector

Metrics to compare
SEPN
Peers
Sector
Relationship
P/E Ratio
−34.3x−4.7x−0.2x
PEG Ratio
−4.110.340.00
Price/Book
4.7x4.1x2.6x
Price / LTM Sales
21.0x6.9x2.8x
Upside (Analyst Target)
39.0%100.4%65.0%
Fair Value Upside
Unlock−3.7%9.6%Unlock

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
8.81M18.87%427.62M
Other Institutional Investors
55.03M81.13%2.67B
Public Companies & Retail Investors
0.000.00%0.00
Total
63.84M100.00%3.1B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Third Rock Ventures, LLC22.02%10,280,050499,199
Third Rock Ventures V, LP13.00%6,068,391294,681

People Also Watch

15.48
NRIX
-0.77%
45.93
EWTX
+0.24%
57.410
LQDA
-1.22%
28.26
ARQT
+2.65%
30.290
AMLX
+1.44%

FAQ

What Is the Septerna (SEPN) Stock Price Today?

The Septerna stock price today is 42.60 USD.

What Stock Exchange Does Septerna Trade On?

Septerna is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Septerna?

The stock symbol for Septerna is "SEPN."

What Is the Septerna Market Cap?

As of today, Septerna market cap is 1.99B USD.

What Is Septerna's Earnings Per Share (TTM)?

The Septerna EPS (TTM) is -1.30.

From a Technical Analysis Perspective, Is SEPN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Septerna Stock Split?

Septerna has split 0 times.

How Many Employees Does Septerna Have?

Septerna has 134 employees.

What is the current trading status of Septerna (SEPN)?

As of 14/11/2026, Septerna (SEPN) is trading at a price of 42.60 USD, with a previous close of 42.60 USD. The stock has fluctuated within a day range of 40.60 USD to 42.88 USD, while its 52-week range spans from 21.31 USD to 53.34 USD.

What Is Septerna (SEPN) Price Target According to Analysts?

The average 12-month price target for Septerna is 59.22 USD, with a high estimate of 65 USD and a low estimate of 48 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +39.02% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.